MRK

Merck & Company Inc

MRK, USA

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

https://www.merck.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.85

Next Payout:

Jan 8, 2026

Yield:

3.4476 %
MRK
stock
MRK

Here's 1 major catalyst behind Merck stock's recent 3.8% bump MSN

Read more →
MRK
stock
MRK

MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? Finviz

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$105.3473

Analyst Picks

Strong Buy

12

Buy

3

Hold

11

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

13.47

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.75

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

11.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.47 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

39.56 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.50

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 64.06% of the total shares of Merck & Company Inc

1.

Vanguard Group Inc

(10.1256%)

since

2025/06/30

2.

BlackRock Inc

(8.7414%)

since

2025/06/30

3.

State Street Corp

(4.744%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(3.1594%)

since

2025/07/31

5.

Wellington Management Company LLP

(3.077%)

since

2025/06/30

6.

Vanguard 500 Index Investor

(2.4885%)

since

2025/07/31

7.

Geode Capital Management, LLC

(2.3602%)

since

2025/06/30

8.

Charles Schwab Investment Management Inc

(2.1565%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(1.7696%)

since

2025/06/30

10.

NORGES BANK

(1.4457%)

since

2025/06/30

11.

Schwab US Dividend Equity ETFâ„¢

(1.3915%)

since

2025/08/30

12.

Fidelity 500 Index

(1.2743%)

since

2025/07/31

13.

JPMorgan Chase & Co

(1.274%)

since

2025/06/30

14.

FMR Inc

(1.2638%)

since

2025/06/30

15.

SPDR® S&P 500® ETF

(1.214%)

since

2025/08/31

16.

iShares Core S&P 500 ETF

(1.2097%)

since

2025/08/31

17.

Northern Trust Corp

(1.1508%)

since

2025/06/30

18.

Bank of America Corp

(1.1218%)

since

2025/06/30

19.

Franklin Resources Inc

(1.0823%)

since

2025/06/30

20.

UBS Asset Mgmt Americas Inc

(1.0062%)

since

2025/06/30

21.

Fisher Asset Management, LLC

(1.0014%)

since

2025/06/30

22.

Vanguard Value Index Inv

(0.891%)

since

2025/07/31

23.

Bank of New York Mellon Corp

(0.8807%)

since

2025/06/30

24.

Vanguard Health Care Inv

(0.7928%)

since

2025/06/30

25.

Legal & General Group PLC

(0.7808%)

since

2025/06/30

26.

Arrowstreet Capital Limited Partnership

(0.7789%)

since

2025/06/30

27.

Goldman Sachs Group Inc

(0.7363%)

since

2025/06/30

28.

The Health Care Select Sector SPDR® ETF

(0.6865%)

since

2025/08/31

29.

Deutsche Bank AG

(0.6823%)

since

2025/06/30

30.

Vanguard Equity-Income Inv

(0.6816%)

since

2025/06/30

31.

Vanguard Institutional Index I

(0.6077%)

since

2025/07/31

32.

Vanguard Dividend Appreciation ETF

(0.5402%)

since

2025/07/31

33.

State St S&P 500® Indx SL Cl III

(0.5366%)

since

2025/08/31

34.

Vanguard High Dividend Yield ETF

(0.3877%)

since

2025/07/31

35.

Vanguard Institutional 500 Index Trust

(0.3839%)

since

2025/07/31

36.

Blackrock Eq Idx Fund CF

(0.3798%)

since

2025/06/30

37.

Franklin Income A1

(0.3203%)

since

2025/07/31

38.

Blackrock Russ 1000 Eq Idx Composite

(0.3156%)

since

2025/06/30

39.

Russell 1000 Index Fund

(0.3115%)

since

2025/08/31

40.

Vanguard Health Care ETF

(0.3106%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

2.58

EPS Estimate

2.37

EPS Difference

0.21

Surprise Percent

8.8608%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(8.5)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(8.5)
GARP
Strong GARP(6.5)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.